Failed to register as Favorite Page
Failed to cancel as Favorite Page
This page is already registered as a Favorite Page
You can't add your company to your favorites.
Latest update： 27/04/2017 14:15:51
Shino Test Corporation
We are expanding our business in Japan and abroad with clinical diagnostic reagents that assist in the early treatment of diseases.
Our company is a chemicals manufacturer established in 1953. We mainly manufacture and sell clinical diagnostic reagents used for the early discovery and treatment of diseases. We have been expanding our business in Japan and abroad. We have experience of doing business in Japan with Eiken, Roche, Wako, and Sekisui, as well as sales in Europe, the USA, China, and Taiwan. We have confidence in our development power. It is sufficiently advanced to manufacture even diagnostic aid reagents for Guillain-Barré syndrome and Fisher syndrome, as well as differential diagnostic reagents for summer-type hypersensitivity pneumonitis. We also possess diagnostic reagents based on our unique technologies. We have a branch in Shanghai, China for overseas expansion. We are promoting the expansion of sales channels through staff assigned in our international department for overseas transactions.
[Company strength] We think it is important to work in unison, which is to be solid as a rock. All of us keep this in mind as we devote ourselves to our company business. We treasure our corporate philosophy of telling the truth and harmony, and we try to create a family-like environment where our staff can talk to each other without reservation. We will continue to manufacture clinical diagnostic reagents that are useful for the early discovery and treatment of diseases. We want to be a company that is capable of contributing to society through clinical examinations with a rock-solid corporate culture as our advantage. [Business description] Our company started manufacturing and sales of clinical diagnostic reagent kits in 1951 as a global pioneer in this field. We have been satisfying various needs at medical sites since our establishment. Our company observes a quality management system (QMS) as the basis of manufacturing pharmaceuticals for thorough quality management on production sites. We were able to establish our position as one of the top companies in the biochemical examination field thanks to the trust of many medical personnel. We are now extending our business from the biochemical inspection field to the fields of immunological and genetic examination. [Industry] Chemical industry [Strength of products/technologies] We have been developing most of our products in-house since our establishment. We can make use of our experience to develop products that satisfy the needs of patients and investigators and manufacture and sell them as in-house products with stable quality. This is one of our company’s advantages. We also have the advantage that we can develop and manufacture new reagents. This includes diagnostic aid reagents for Guillain-Barré syndrome and Fisher syndrome as well as differential diagnostic reagents for summer-type hypersensitivity pneumonitis. HMGB1, Periostin, and other items that we developed using our unique technologies have world-class product capabilities. [Representative's message] Our company has developed products using unique technologies in addition to our world-first product HMGB1. We will establish new clinical significance through joint research with overseas research organizations and develop products that widely acceptable throughout the world. We will showcase sensitivity enhanced by developing new technologies and stability improved by devising manufacturing methods to expand sales channels overseas for our existing products. [Company structure for market development/overseas expansion] Our company is establishing an in-house system by setting up an international department and assigning overseas staff. We established a branch in Shanghai about 15 years ago and have been expanding sales channels for our main products. We have also done business in Taiwan, and we are now taking on the challenge of expanding our sales channels to Korea, South America, and Southeast Asia. We have sold newly developed reagents in Europe and America, and we will continue to expand our sales channels. [Market share/Ranking] We have a 14.1% share of the market for clinical diagnostic reagents in the biochemical field. (Aggregated by our company from a 2012 study by the Japanese Association of Medical Technologists, according to the number of biochemical items employed.) [Awards and media coverage] [Awards] Excellent factory commendation by Kanagawa Prefecture for our Sagamihara Production Center (January 2015). [Media] [Authorization/Certification] Nine businesses: Manufacture and sale of pharmaceuticals for extracorporeal diagnosis, manufacture of pharmaceuticals for extracorporeal diagnosis, sales of pharmaceuticals, repairs of medical devices, sales of specially controlled medical devices, and other sales and rental businesses. [Joint research and development] Number of patents applied for: Nine (2013 to 2014). [Main Clients / Business History (domestic)] Consignment manufacturing for Eiken, Roche, Wako, and Sekisui. [Main Clients / Business History (overseas)] Product sales to China, Taiwan, the EU, and the USA.
This company is recommended by the following support organizations.
- Kanto Head Office, SMRJ